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Summary 4-Hydroxyanisole (4-OHA) was administered to C57Bl/lOJ mice in which B16 melanoma or
Lewis lung carcinoma had been implanted s.c. or i.m. The drug had the largest antitumour effect against B16
melanoma growing s.c. and a smaller antitumour effect against B16 melanoma or Lewis lung carcinoma
growing i.m. In the treatment regimens where drug was administered only after tumour implantation, a
significant reduction in number of spontaneous metastases and their incidence was observed. Again, the
largest antimetastatic effect was observed for s.c. B16 melanoma with smaller effects observed for i.m. B16
melanoma or Lewis lung carcinoma. Experiments in which 4-OHA treatment was initiated after amputation
of the primary tumour implanted in the tail confirmed that 4-OHA did have antitumour activity against
disseminated tumour cells. The drug regimens studied to date produced significant delays in the appearance of
spontaneous metastases in the lungs and significant increases in the life spans of the treated animals.
The discovery of melanocytotoxic activity of certain
phenolic depigmenting agents due to their oxidation
by tyrosinase, the 'clue' enzyme in cellular pigment
formation, appeared to offer a therapeutic potential
in the treatment of melanotic melanoma. Animal
studies on experimental melanomas have given
variable results as regards the therapeutic efficacy
of these agents (Chavin & Schlesinger, 1967; Frenk
& Ott 1971; Bleehen, 1973; Paslin, 1973). Several
other phenolic compounds with antioxidant
properties were tested more recently for antitumour
activity against murine melanomas (Demopoulos et
al., 1976; Kanclerz and Zbytniewski, 1981; Kanclerz
et al., 1981; Kanclerz, 1984). The most active
melanocytotoxic agent, to date, is an analog of
tyrosine, 4-hydroxyanisole (4-OHA). Studies in vitro
demonstrated its cytotoxicity against mammalian
melanocytes (Riley et al., 1975; Breathnach et al.,
1983), including human melanoma cells (Bleehen,
1976; Kanclerz & Aubert, 1984; Meyskens, 1984).
Dewey et al. (1977) observed 'regression' of
Harding-Passey melanoma in 46% of the animals
treated with intratumoural application of 4-OHA.
Webster et al. (1984) did not see any significant
difference in weight of intramuscularly growing B16
melanoma after i.p. administration of 4-OHA,
although a two day delay in appearance of tumours
was noticed.
Clinical trials to evaluate the efficacy of 4-OHA
therapy against human melanoma have been
initiated. A small antitumour effect was found after
i.v. or intratumoural application of the drug (Riley
et al., 1982; Webster et al., 1984) and intra-arterial
infusion of 4-OHA seemed to provoke regression of
recurrent melanoma in some cases (Morgan et al.,
1981; Morgan, 1984).
This brief review of the literature reveals that
evidence for an antitumour effect of 4-OHA on
melanoma in vivo is variable and not conclusive,
and that further evaluation and assessment of the
agent was indicated. Previous studies had not specifi-
cally determined whether 4-OHA can influence
tumour cell dissemination. This pathological
phenomenon is of clinical importance since lethality
of melanoma depends, to a large extent, upon
the invasive properties of malignant melanocytes
and their capacity to form secondary foci within
the host.
Materials and methods
Animals
Male C57B1/1OJ mice were bred at the Medical
Sciences Building Animal Centre of the University
of Alberta and delivered to the Cross Cancer
Institute when weaned. Experiments were initiated
with animals of 8-10 weeks of age and weights of
25-30 g. They were maintained at 21 + 1°C on a
10h light/14h dark cycle, housed 5 to a cage
containing sterilized wood chip bedding and
allowed free access to water and to standard rodent
laboratory chow (No. 5001, Ralston Purina Co., St
Louis, MO).
Tumours
The two animal tumours investigated were Lewis
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lung carcinoma (LLC) and pigmeneted B16
melanoma; original stock of each was from the
Institute of Cancer Research, London, England.
Tumours were maintained in vivo by a serial i.m.
transplantation in C57B1/10J mice. Cells were
mechanically isolated from solid tumours and
suspended in minimal essential medium to obtain
the final concentration of 106 tumour cells per
injection site. Cell viability was >80% by the trypan
blue exclusion test and by phase-contrast
microscopy. Aliquots (0.05ml) from the same cell
suspension were injected into the gastrocnemius
muscle or subcutaneously into the right flank of
animals in random order. Another method of
tumour transplantation consisted of mincing donor
tissue into - 1 mm fragments and implanting s.c.
into the tails. Tumours were allowed to metastasize
naturally from that site and the tails with primary
tumours were amputated at various times.
Chemicals
4-OHA was reagent grade and purchased from
Sigma, St Louis, MO. The chemical was
recrystallized from xylene, placed under vacuum for
24h to remove solvent and stored in a dessicator
prior to use. The substance was dissolved at a
concentration of 0.1 M in sterile 0.9% NaCl
solution and passed through a 0.24um millipore
filter immediately before administration to animals.
Treatment schedules
Different treatment regimens were used in these
studies. 4-OHA was administered i.p. in all
experiments and control groups of tumour bearing
animals were injected with an equivalent volume of
0.9% NaCl solution.
Treatment regimen A Consisted of five injections
of the drug at 50mgkg-I on days 3 to 7 after
tumour transplantation as described previously
(Kanclerz & Chapman, 1986).
Treatment regimen B Additional drug dosage
schedules were investigated with tumours implanted
s.c. and/or i.m. for the purpose of increasing the
antitumour effect of 4-OHA. 4-OHA was
administered at 50mgkg-1 twice daily (in some
cases for up to 28 days) until the tumour bearing
animals were sacrificed for analysis. The effects of
pretreating animals with 50mgkg-t 4-OHA twice
daily for 5 days prior to tumour implantation was
measured as well. Three different schedules applied
are presented in Figure 1.
Treatment regimen C: Surgery and 4-OHA
administration Animals were injected with 4-OHA
at 50mgkg-1, twice daily for 5 days before or 5
days after tumour surgery (Table II).
Data collection
Each control or experimental group consisted of
13-15 animals unless otherwise stated. Tumour
volumes were computed from three external
diameters measured serially with calipers three
times a week and assuming that the tumours were
ellipsoids. These volumes were corrected for skin
thickness, in case of tumours growing sub-
cutaneously, and gastrocnemius muscle volume, for
tumour growing intramuscularly. Weight of the
tumours was determined at the time of animal
sacrifice or at their spontaneous death.
The development of spontaneous metastases to
the lungs and to the other organs was assessed by
careful autopsies performed on each animal. The
lungs were removed, rinsed in cold 0.9% NaCl
solution, weighed and then placed in Bouin's
solution for 24h fixation. Metastases observed in
each pair of the animals' lungs were scored with the
aid of a dissecting microscope.
Statistical methods
Volume and mass changes of the primary tumours,
the weight of the lungs as well as of the lymph
node metastases in control and treated groups were
analyzed using the Student's t-test. Differences in
number of pulmonary metastases were evaluated by
the non-parametric Mann-Whitney U-Wilcoxon
rank sum W test. Incidence of metastases was
compared by the test of proportions and median
survival time of animals calculated according to the
Kaplan and Meier method. P values of 0.05 or
lower were considered significant.
Results
Treatment regimen A
A small, but significant, inhibition of primary B16
melanoma growth was observed. On day 21 after
tumour implantation, tumour volumes (and
weights) were consistently lower in the group of 4-
OHA treated animals. The average number of
metastases in 4-OHA treated and control animals
was 4.2 and 7.1, respectively, and the incidence of
metastases was 68.4% vs. 83.3%, respectively.
Treatment regimen B
4-OHA retarded the growth of primary s.c. B16
melanoma in the groups of animals treated after
tumour cell inoculation (Figure 2). It had little or
no effect on the growth of primary i.m. B164-HYDROXYANISOLE TREATMENT OF ANIMAL TUMOURS 695
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Figure 1 Treatment protocols of Lewis lung carcinoma and melanotic B16 melanoma for the more
aggressive therapy (treatment regimen B): 4-OHA administered i.p. at 50mgkg-' twice daily, control groups
injected twice daily with equivalent vol of sterile physiologic saline.
melanoma and had no effect on the growth of
primary LLC (data not shown). In fact,
pretreatment of animals with 4-OHA had a small,
but significant, potentiating effect on growth of
both tumours (schedule D, Figure 1).
The average number of B16 melanoma
pulmonary metastases per pair of lungs was
significantly lower in 4-OHA treated animals for
both growth sites (s.c. and i.m.) investigated
(Table 1). These effects were larger in the animals
having s.c. tumour. The average number of LLC
pulmonary metastases per animal was significantly
lower in the mice treated with 4-OHA after tumour
transplantation; however, 4-OHA pretreatment
alone increased the number of metastases in the
lungs.
Treatment regimen C
The number of metastases per pair of lungs was
lower in all groups treated after tumour removal
with the largest effect observed in the mice whose
tumours had been amputated the earliest. Similarly,
the wet weight of the lungs was lower in all
experimental groups (Table II). A slight increase in
the number of pulmonary metastases and an
increase of lung mass were observed in the animals
treated with 4-OHA before surgery performed on
day 23 (Table II). The median survival time was
longer in the groups of animals to which 4-OHA
was administered after tumour removal (Figure 3).
The experiments carried out on LLC revealed no
differences in the number of pulmonary metastases
nor in the lung weight between animals treated with
4-OHA before or after surgery and controls,
although the treated animals survived longer than
the non-treated ones (P>0.01).
Metastases of both tumours to lymph nodes were
observed in all the groups of animals. Their
frequency and their weights showed no differences
between drug treated and control mice.
Discussion
The reported effects of 4-OHA on experimental
melanomas are highly variable, showing no
response in some systems and complete remission of
murine tumours in others (Dewey et al., 1977;
Webster et al., 1984). Moreover, the effect of 4-
OHA on naturally occurring metastases in animals
has not been reported. In spite of these limited
laboratory results the first clinical observations on a
small number of treated patients suggest efficacy
of 4-OHA therapy against secondary melanoma
(Riley et al., 1982; Morgan et al., 1984).
In our experiments we were able to measure a
small, but significant, beneficial effect of 4-OHA
therapy. Administration of 4-OHA in five i.p.
injections from day 3 to 7 after tumour
transplantation resulted in a relatively small,
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altnougn statistically signiticant, inhibition of the
primary melanoma growth and had some inhibit-
ing effect on spontaneous metastases formation.
Effects of 4-OHA applied in a similar regimen
to animals bearing Lewis lung carcinoma were
transient and less evident than in the case of
pigmented B16 melanoma (Kanclerz & Chapman,
1986). Some increase of pulmonary LLC metastases
was seen at different times after tumour challenge
in experiments with i.m. growing tumours.
Since 4-OHA is a relatively nontoxic substance
an additional therapy was applied to determine if
the effects of 4-OHA could be enhanced. This more
aggressive therapy was accomplished by increasing
the time and frequency of drug administration and
hence augmenting the total dose given (Figure 1).
Inhibition of s.c. melanoma growth was observed
with this treatment (Figure 2) and a lower number
of pulmonary metastases and their incidence was
observed in these animals (Table I). However, we
were not able to observe any growth inhibition of
melanoma growing i.m. An analysis of the tumour
volumes revealed that tumours growing i.m. were
more than 4 times larger than those growing s.c. at
the time of treatment. It could be that the drug
availability in the i.m. melanoma tissue was not
adequate to produce any significant therapeutic
effects in the faster growing tumours. In spite of the
absence of any effect on the growth of i.m.
melanomas, an inhibition of metastatic spread to ilanted B16 the lungs was observed (Table I). Taking into
faform of account animals with pulmonary metastases only
irrors bars (some did not develop lung nodules) a decrease in
,cording to the average number of lung colonies in mice with
it schedules both s.c. or i.m. tumours was observed. The effect
(E LE); of 4-OHA on pulmonary metastases shown in
Table I Number and incidence of spontaneous metastases of B16 melanoma to the lungs in
animals treated with 4-OHA according to Figure 1.
Mean number ofmetastases per animal
Number Total, including Incidence of
of animals without Only animals metastasesc
Group animals metastases with metastases Range (%)
A 14 9.7 13.6 0-58 71.4
B16 B 13 2.5 (P=0.036)a 10.7 0-19 23.1 (p=0.004)b
s.c. C 9 0.9 (P=0.035)a 4.0 0-6 22.2 (P=0.007)b
D 13 3.9 6.4 0-23 61.5
A 15 5.1 6.9 0-51 73.3
B16 B 15 4.5 6.8 0-23 66.7
im C 15 1.1 (P=0.15)a 2.4 0-4 46.7 (P=0.12)b
D 15 4.3 7.2 0-42 60.0
aMann-Whitney U-Wilcoxon rank sum W test; bTest of proprtions and cPercentage of animals
with metastases over total number ofexperimental animals in the group.
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Table II Dissemination of B16 melanoma from the tail to the lungs in animals
tumour amputation.
given 4-OHA before or after
Post-surgery treatment Pre-surgery treatment
Day ofsurgery
(after tumour implantation) 18 23 28 23
Treated
Wet weight of the 457.5+233.4 599.7+229.7b 666.3 +485.6 981.4+ 146.6b
lungs [mg±s.e.]
Control
607.5+197.4 1022.8+141.2 907.5+301.0 584.6+201.1
Treated
Mean number of metastases 9.5 (1-l9)' 14.0 (0-25) 12.7 (0-38) 39.1 (8-127)
per animal (range)
Control
21.8 (0-76) 34.6 (12-58) 19.8 (0-38) 30.6 (1-98)
ap=0.05: Mann-Whitney U-Wilcoxon rank sum W test; bp>0.1: Student's t-test.
In these experiments, the incidence of metastases in a group was 86-100%.
T0- P< 0.05 P< 0.05 ~rao
2 30-- t 0; *Control
1O_
Surgery on day +23 +18 +23 +28
4-OHA treatment
Before After
surgery surgery
Figure 3 Median survival time of animals with pigmented B16 melanoma after removal
tumour transplanted s.c. on the tail. P calculated after Kaplan and Meier.
of the primary
Table I suggests activity of 4-OHA on metastases
formation.
No response on LLC of the more aggressive
therapy applied before or after tumour challenge
was observed. Some growth promotion was
measured when 4-OHA administration was carried
out before tumour transplantation only (schedule
D). Nonetheless, a 30% decrease in the number of
lung nodules was observed in animals treated after
tumour cell inoculation. This inhibiting effect was
much smaller than that observed with pigmented
B16 melanoma. An increased dosage of the drug
resulted in an enhanced efficacy of the applied
treatment. In particular, a larger inhibition of
spontaneous metastases formation to the lungs was
found: more pronounced for pigmented tumour and
slight for LLC. These decreased numbers of
pulmonary deposits observed in our experiments
may reflect different targets of 4-OHA action: the
primary tumour itself, disseminated cells or a
combination of both. Lower tumour volume and
mass due to a successful treatment and a sub-
sequent decrease of cell population would result in
a less efficient source of viable cells, potential
precursors of metastatic nodules. In order to distin-
guish if 4-OHA inhibiting action on metastases is
caused by its influence on disseminated cells and
not only on the primary neoplasia, tumours were
transplanted to mouse tails and both the circulating
and microscopic foci of tumour cells were treated
systemically after tumour amputation. In separate
experiments, some animals were subjected to 4-
OHA application before surgery only. A decrease in
number of melanoma metastases in animals treated
after tumour amputation implies 4-OHA activity
against cells spread within the host body. The
metastases inhibiting effect is largest in the group of
animals having the tumours removed at the earliest698 A. KANCLERZ & J.D. CHAPMAN
time after implantation, i.e. on day 18, when the
burden of disseminated disease is presumably low
(Table II).
The more pronounced effects of the applied 4-
OHA treatment on B16 melanoma and its
metastatic spread suggest specificity of the com-
pound against pigmented tumour which is com-
patible with previously published results. Similarly,
we observed longer survival times (up to 12 days) in
animals treated after melanoma removal as
compared to 3 days for mice having amputated
LLC (Figure 3). However, 4-OHA did not modify
the spread of either tumour to the lymphatic
system.
Our data suggest that 4-OHA has a moderate
growth retarding effect on primary B16 melanoma.
The finding that the antioxidant has some potential
to suppress metastatic spread is of interest,
particularly when considering that metastatic
dissemination is a major cause of death due to
cancer (Weiss, 1985). 4-OHA effectiveness on B16
metastases formation appears most effective when
the burden of disseminated disease is small.
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